CLINICAL_TRIALS
trial_result
· 2018-12-19
Clinical Trial Update: Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. [Phase 3]
Summary
A Phase 3 study evaluating orteronel plus prednisone in metastatic castration-resistant prostate cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-12-19